BR112017011513A2 - tratamento de condições oculares usando células progenitoras - Google Patents

tratamento de condições oculares usando células progenitoras

Info

Publication number
BR112017011513A2
BR112017011513A2 BR112017011513A BR112017011513A BR112017011513A2 BR 112017011513 A2 BR112017011513 A2 BR 112017011513A2 BR 112017011513 A BR112017011513 A BR 112017011513A BR 112017011513 A BR112017011513 A BR 112017011513A BR 112017011513 A2 BR112017011513 A2 BR 112017011513A2
Authority
BR
Brazil
Prior art keywords
progenitor cells
treatment
eye conditions
cells
neuronal
Prior art date
Application number
BR112017011513A
Other languages
English (en)
Portuguese (pt)
Inventor
Harris Ian
Sophia DEJNEKA Nadine
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of BR112017011513A2 publication Critical patent/BR112017011513A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Analytical Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112017011513A 2014-12-05 2015-12-04 tratamento de condições oculares usando células progenitoras BR112017011513A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462088429P 2014-12-05 2014-12-05
US201562126370P 2015-02-27 2015-02-27
US201562220873P 2015-09-18 2015-09-18
PCT/US2015/063923 WO2016090215A2 (en) 2014-12-05 2015-12-04 Treatment of ocular conditions using progenitor cells

Publications (1)

Publication Number Publication Date
BR112017011513A2 true BR112017011513A2 (pt) 2018-07-10

Family

ID=56092673

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011513A BR112017011513A2 (pt) 2014-12-05 2015-12-04 tratamento de condições oculares usando células progenitoras

Country Status (16)

Country Link
US (1) US20160158293A1 (https=)
EP (1) EP3258946A4 (https=)
JP (1) JP2017537702A (https=)
KR (1) KR20170093178A (https=)
CN (1) CN107206028A (https=)
AU (1) AU2015358330A1 (https=)
BR (1) BR112017011513A2 (https=)
CA (1) CA2969690A1 (https=)
HK (1) HK1250329A1 (https=)
MX (1) MX2017007207A (https=)
PH (1) PH12017500998A1 (https=)
RU (1) RU2017123184A (https=)
SG (1) SG11201704268TA (https=)
TW (1) TW201636032A (https=)
WO (1) WO2016090215A2 (https=)
ZA (1) ZA201704521B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
WO2018102174A1 (en) * 2016-12-01 2018-06-07 Janssen Biotech, Inc. Treatment of retinal degeneration using progenitor cells
GB201703058D0 (en) 2017-02-24 2017-04-12 Ucl Business Plc Biomarkers
JP7348892B2 (ja) * 2019-12-30 2023-09-21 佛教慈濟醫療財團法人 眼疾患を予防または治療する組成物及び方法
WO2021207282A2 (en) * 2020-04-07 2021-10-14 Combangio, Inc. Lyophilized mesenchymal stem cell derived secretome and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399990B1 (en) * 2003-06-27 2015-07-22 DePuy Synthes Products, Inc. Cells derived from post-partum umbilical cord for use in treatment of disease of the heart and circulatory system
US8790637B2 (en) * 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
EP2431460B1 (en) * 2009-05-13 2015-10-14 Medipost, Co., Ltd. Tsp-1, tsp-2 and il-17br associated with stem cell differentiation
KR101462004B1 (ko) * 2011-07-11 2014-11-19 (주)차바이오메드 탯줄 추출물의 제조방법 및 그의 용도
US20130251670A1 (en) * 2011-09-13 2013-09-26 Aidan Products, Inc Treatment of Macular Edema Utilizing Stem Cell and Conditioned Media Thereof

Also Published As

Publication number Publication date
HK1250329A1 (zh) 2018-12-14
JP2017537702A (ja) 2017-12-21
RU2017123184A3 (https=) 2019-07-17
RU2017123184A (ru) 2019-01-10
EP3258946A4 (en) 2018-08-01
TW201636032A (zh) 2016-10-16
MX2017007207A (es) 2018-01-30
PH12017500998A1 (en) 2017-12-18
KR20170093178A (ko) 2017-08-14
EP3258946A2 (en) 2017-12-27
CA2969690A1 (en) 2016-06-09
WO2016090215A2 (en) 2016-06-09
US20160158293A1 (en) 2016-06-09
AU2015358330A1 (en) 2017-06-08
SG11201704268TA (en) 2017-06-29
ZA201704521B (en) 2019-01-30
CN107206028A (zh) 2017-09-26

Similar Documents

Publication Publication Date Title
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
MX389789B (es) Moléculas del receptor de envolvimiento quimérico.
HK1252568A1 (zh) 一种治疗方法
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
GT201400162A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
WO2016037157A3 (en) Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112017012581A2 (pt) tratamento de degeneração da retina com o uso de células progenitoras
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
CL2017001301A1 (es) Composiciones oftálmicas estabilizadas de omega 3
WO2017066712A3 (en) Modulators of telomere disease
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
BR112017011513A2 (pt) tratamento de condições oculares usando células progenitoras
MX382488B (es) Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas.
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
SG10201804034QA (en) Methods for treating hypotension
BR112016029632A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de cinase
EA201991360A1 (ru) Модифицированные олигонуклеотиды для лечения поликистозной болезни почек
EA201592265A1 (ru) Маркер для ассоциированных с кислой сфингомиелиназой нарушений и его применения
BR112016029460A2 (pt) métodos para tratar artrite reumatoide
WO2015149006A3 (en) Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
WO2015138761A3 (en) Methods for treating peripheral nerve damage
EA201792603A1 (ru) Ангиогенез с использованием стимулированных плацентарных стволовых клеток
MX390967B (es) Composiciones y métodos para la modulación de la actividad at2r
MX2019015273A (es) Moduladores de alfa-sinucleinca.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements